NasdaqGS:AMRXPharmaceuticals
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments
Amneal Pharmaceuticals (NasdaqGS:AMRX) reported strong Q4 2025 results, highlighting progress across specialty, injectables, biosimilars, and complex generics.
The company announced multiple product launches and regulatory approvals, expanding its presence in higher value segments.
Management highlighted a promising pipeline, including biosimilars expected to enter the US market.
Amneal also emphasized its collaboration with Pfizer on GLP-1 therapies as a key focus area for future...